Holen Sie sich die Stockscreener-App
0.00
100.00%
-0.157
Schlusskurs vom Vortag:
$0.157
Offen:
$0
24-Stunden-Volumen:
0
Relative Volume:
0.00
Marktkapitalisierung:
$11.00M
Einnahmen:
$1.16M
Nettoeinkommen (Verlust:
$-39.74M
KGV:
0.00
EPS:
-0.62
Netto-Cashflow:
$-35.02M
1W Leistung:
-100.00%
1M Leistung:
-100.00%
6M Leistung:
-100.00%
1J Leistung:
-100.00%
1-Tages-Spanne:
$0.00
$0.00
1-Wochen-Bereich:
$0.00
$0.00
52-Wochen-Spanne:
$0.00
$0.63
Glycomimetics Inc Stock (GLYC) Company Profile
Firmenname
Glycomimetics Inc
Sektor
Branche
Telefon
240-243-1201
Adresse
9708 MEDICAL CENTER DRIVE, ROCKVILLE, MD
Vergleichen Sie GLYC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GLYC
Glycomimetics Inc
|
0.00 | 11.00M | 1.16M | -39.74M | -35.02M | -0.62 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.49 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.70 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.50 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
572.87 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
296.12 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Glycomimetics Inc Stock (GLYC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-14 | Eingeleitet | Wedbush | Outperform |
| 2025-06-25 | Eingeleitet | Stifel | Buy |
| 2025-03-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-07-26 | Herabstufung | TD Cowen | Buy → Hold |
| 2023-12-22 | Eingeleitet | CapitalOne | Overweight |
| 2021-11-12 | Hochstufung | Jefferies | Hold → Buy |
| 2019-11-14 | Eingeleitet | ROTH Capital | Buy |
| 2019-08-05 | Herabstufung | Jefferies | Buy → Hold |
| 2019-08-05 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2019-08-05 | Herabstufung | SunTrust | Buy → Hold |
| 2019-04-12 | Eingeleitet | Piper Jaffray | Overweight |
| 2018-12-18 | Eingeleitet | H.C. Wainwright | Buy |
| 2016-07-26 | Eingeleitet | SunTrust | Buy |
| 2015-03-17 | Bestätigt | Stifel | Buy |
Alle ansehen
Glycomimetics Inc Aktie (GLYC) Neueste Nachrichten
What analysts say about GlycoMimetics Inc. stockConsistent high-yield stocks - Autocar Professional
GlycoMimetics Inc. Stock Analysis and ForecastFastest return on investment - Autocar Professional
Is GlycoMimetics Inc. a good long term investmentRapid growth opportunities - jammulinksnews.com
What drives GlycoMimetics Inc. stock priceTremendous return rates - jammulinksnews.com
Why GlycoMimetics Inc. stock attracts strong analyst attentionSmart Return Focused Trading - Newser
How GlycoMimetics Inc. stock performs during market volatility200 Percent Profit Outlook - Newser
What makes GlycoMimetics Inc. stock price move sharplySmart Money Trade Setups - Newser
Wedbush Initiates Crescent Biopharma at Outperform With $27 Price Target - MarketScreener
GlycoMimetics (NASDAQ:CBIO) Rating Increased to Strong-Buy at Lifesci Capital - Defense World
Crescent Biopharma to Present at Jefferies London Healthcare Conference 2024 - MarketScreener
Crescent Biopharma Completes Merger with GlycoMimetics - TipRanks
Crescent Biopharma Completes Merger With GlycoMimetics - MarketScreener
Balance Sheet Dive: GlycoMimetics Inc (GLYC)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - DWinneX
Crescent Biopharma Completes Closing of Merger with GlycoMimetic - GuruFocus
Crescent Biopharma Completes Closing of Merger with GlycoMimetics and Previously Announced Private Placement of $200 Million | CBIO Stock News - GuruFocus
Crescent Biopharma Completes Closing of Merger with - GlobeNewswire
Crescent Biopharma Completes Closing of Merger with GlycoMimetics and Previously Announced ... - Bluefield Daily Telegraph
Massive $200M Biotech Deal: Crescent Biopharma Secures Funding for Cancer Breakthrough Pipeline - Stock Titan
GlycoMimetics, Inc. Announces Board Changes - MarketScreener
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CMRX and GLYC on Behalf of Shareholders - MarketScreener
GlycoMimetics Announces Chief Executive Officer Changes - MarketScreener
GlycoMimetics (GLYC) Trading Halt Sparks Anticipation | GLYC Sto - GuruFocus
GlycoMimetics (GLYC) Trading Halt Sparks Anticipation | GLYC Stock News - GuruFocus
GlycoMimetics (NASDAQ:GLYC) Shares to Reverse Split on Monday, June 16th - Defense World
Cantor Fitzgerald Comments on GlycoMimetics FY2026 Earnings - Defense World
Where Do Analysts Think The GlycoMimetics Inc (NASDAQ: GLYC) Is Going - Stocksregister
Wellington Management Group LLP Takes Position in GlycoMimetics, Inc. (NASDAQ:GLYC) - Defense World
GlycoMimetics Stockholders Approve Merger with Crescent Biopharma - TipRanks
GlycoMimetics Stockholders Approve Proposed Merger With Crescent Biopharma And All Related Proposals - marketscreener.com
GlycoMimetics Stockholders Approve Merger with Crescent Biopharma and All Related Proposals - citybiz
GlycoMimetics (GLYC) Stockholders Approve Merger with Crescent Biopharma | GLYC Stock News - GuruFocus
GlycoMimetics announces 1-for-100 reverse stock split - Investing.com Australia
GlycoMimetics announces 1-for-100 reverse stock split By Investing.com - Investing.com Canada
GlycoMimetics stockholders approve proposed Crescent Biopharma merger - TipRanks
GlycoMimetics Stockholders Approve Proposed Merger with Crescent Biopharma and All Related Proposals - Business Wire
Finanzdaten der Glycomimetics Inc-Aktie (GLYC)
Umsatz
Nettogewinn
Free Cashflow
ENV
Glycomimetics Inc-Aktie (GLYC) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Invus Public Equities, L.P. | 10% Owner |
Aug 07 '24 |
Sale |
0.18 |
61,488 |
11,197 |
6,578,438 |
| Invus Public Equities, L.P. | 10% Owner |
Aug 05 '24 |
Sale |
0.19 |
164,523 |
30,996 |
6,695,658 |
| Invus Public Equities, L.P. | 10% Owner |
Aug 06 '24 |
Sale |
0.18 |
55,732 |
10,188 |
6,639,926 |
| Invus Public Equities, L.P. | 10% Owner |
Aug 02 '24 |
Sale |
0.20 |
286,200 |
57,354 |
6,860,181 |
| Invus Public Equities, L.P. | 10% Owner |
Aug 01 '24 |
Sale |
0.22 |
63,564 |
13,743 |
7,146,381 |
| Invus Public Equities, L.P. | 10% Owner |
Jul 30 '24 |
Sale |
0.22 |
756,835 |
167,185 |
7,209,945 |
| Invus Public Equities, L.P. | 10% Owner |
Jul 29 '24 |
Sale |
0.24 |
363,949 |
85,637 |
7,966,780 |
| Invus Public Equities, L.P. | 10% Owner |
Jul 26 '24 |
Sale |
0.24 |
258,335 |
62,440 |
8,330,729 |
4.75%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):